Related Experiment Video
Updated: Apr 20, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Is the evidence of the Supreme Court Ruling of gefitinib litigation in Japan scientific?
K Katahira1, T Yoshikawa2, H Enoki3
1Faculty of Social Welfare, Niigata University of Health and Welfare, Niigata, Japan Institute of Clinical and Social Pharmacy, Saitama, Japan.
Background:
Plaintiffs of the gefitinib (Iressa) lawsuits in Japan started in 2004 were defeated in the Supreme Court in 2013. The Court judged it was not possible to foresee the outbreak of deaths caused by interstitial pneumonia due to gefitinib from death cases before approval of this drug.
Objective:
We attempted to verify validity of this judgment.
Methods:
We estimated the 95% confidence interval (CI) of the proportion of onset and death cases among 23 onset and 13 death cases occurring from "within 1 week" to "within 4 weeks" from clinical data before approval of this drug using data admitted to the Court.
Results:
For death cases, all of the upper limits of the 95% CI exceeded 50% within 1-4 weeks. This fact suggested that the cases of acute interstitial pneumonia were included in the clinical trial before the approval of gefitinib.
Conclusion:
It was possible to foresee the outbreak of death cases after drug approval. This conclusion showed the Court's ruling was not reasonable and was unscientific.
More Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Regulation
Treatment Resistent Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence studies: Biowaivers
Clinical Trials: Overview